ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 ...

ZIOPHARM Oncology Announces Positive Updated Results of Ad-RTS-hIL-12 ...


ZIOPHARM Oncology, Inc. , a biopharmaceutical company focused on new immunotherapies, today announced updated results from its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex including the 20 mg expansion cohort in patients with recurrent or progressive glioblastoma at the 2017 American Society of Clinical Oncology Annual Meeting June 2-6 in Chicago. In a poster presentation titled "Expanded phase I study of intratumoral Ad-RTS-hIL-12 + oral veledimex: tolerability and survival in recurrent glioblastoma," the Company reported results from 25 patients with recurrent or progressive Grade III or IV glioma enrolled in three veledimex dosing cohorts .



from Biotech News